Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | GLP-1 / Glucagon Dual Survodutide |
|---|---|
| Summary | Dual GLP-1/glucagon agonist — competes with retatrutide on potency. |
| Mechanism | Co-agonist of GLP-1 and glucagon receptors — adds energy expenditure on top of appetite suppression. |
| Top outcomes |
|
| Evidence | emerging |
| Half-life | ~6-7 days |
| Administration | subq |
| Legal status | research only |
| Safety | Nausea, vomiting; cardiovascular monitoring required due to glucagon activity. |